ALLECRA THERAPEUTICS
Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacteria... l infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France
ALLECRA THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2013-01-01
Address:
Weil Am Rhein, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.allecra.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
37 M EUR
Technology used in webpage:
Common Name Invalid CPanel 10 To 14 CcTLD Redirects
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Zolex Therapeutics
Zolex Therapeutics focuses on the development of new classes of orally-active antibiotics to combat life-threatening bacterial infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series B - Allecra Therapeutics
Delos Capital
Delos Capital investment in Series B - Allecra Therapeutics
Nicholas Benedict
Nicholas Benedict investment in Series B - Allecra Therapeutics
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Series B - Allecra Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Allecra Therapeutics
EMBL Ventures
EMBL Ventures investment in Series B - Allecra Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Allecra Therapeutics
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Series A - Allecra Therapeutics
EMBL Ventures
EMBL Ventures investment in Series A - Allecra Therapeutics
Andera Partners
Andera Partners investment in Series A - Allecra Therapeutics
Official Site Inspections
http://www.allecra.com Semrush global rank: 7 M Semrush visits lastest month: 940
- Host name: ec2-46-137-120-152.eu-west-1.compute.amazonaws.com
- IP address: 46.137.120.152
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Allecra Therapeutics"
allecra - home
Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance …See details»
allecra - home
Allecra Therapeutics GmbH Wallbrunnstr. 24 79539 Lörrach Germany +49-761-45899872 ...See details»
Allecra Therapeutics - Crunchbase Company Profile
Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β …See details»
Organization | Allecra
Organization Overview. First Clinical Trial. 2013 NCT03685084. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Allecra | ALLECRA THERAPS Active Ingredients. …See details»
Allecra Therapeutics Company Profile - Office Locations, …
Dec 21, 2020 Allecra Therapeutics is a clinical stage biopharmaceutical company, develops pharmaceuticals to treat gram-negative multidrug-resistant bacterial infections. Its mission is to …See details»
Allecra Therapeutics Company Profile 2024: Valuation, Funding ...
Allecra Therapeutics General Information Description. Developer of novel antibiotics designed to combat gram-negative bacterial infections. The company's novel antibiotics are used to treat …See details»
Scientific Information - allecra
Sep 5, 2019 Allecra is focused on the treatment of Gram-negative multi drug-resistant infections. Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae have been categorized as …See details»
Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License …
Jan 13, 2022 Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace. Please visit www.allecra.com for further information and …See details»
Allecra Therapeutics and ADVANZ PHARMA Sign …
Jan 13, 2022 Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms.See details»
Allecra Therapeutics and Acino Sign Exclusive Licensing …
Jun 24, 2024 For Allecra Therapeutics: Andreas Kranzusch, Chief Financial Officer and Managing Director [email protected] Gretchen Schweitzer, Trophic Communications, +49 172 8618540 [email protected] For Acino ...See details»
Allecra Therapeutics and Acino Sign Exclusive Licensing and …
Jun 24, 2024 Acino and Allecra Therapeutics Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf …See details»
Antimicrobial Resistance - allecra
Allecra is developing an extended spectrum BLI that restores the effectiveness of cefepime, a powerful antibiotic, even in the face of some potent, emerging, β-lactamase mediated …See details»
ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP® …
Jan 26, 2024 Allecra has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors are: Forbion, Andera Partners, Delos Capital, Xeraya …See details»
FDA approves cefepime/enmetazobactam for complicated UTI
Feb 27, 2024 In addition to the approval, the FDA has also granted Allecra a 5-year marketing exclusivity extension for cefepime/enmetazobactam as part of the Generating Antibiotic …See details»
Allecra Therapeutics successfully enters next development phase
Allecra Therapeutics GmbH Bert Tjeenk Willink Chairman of the Advisory Board [email protected] About Allecra Therapeutics Allecra Therapeutics, established in 2013, is a clinical-stage …See details»
Allecra Therapeutics Announces Positive Top-Line Results for …
Feb 25, 2020 Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections ... the development of …See details»
Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP …
Feb 27, 2024 Allecra is the sole holder of a significant patent estate covering EXBLIFEP ® in major territories with the GAIN Act extending Allecra’s market exclusivity until 2032. …See details»
20240227 Allecra FDA Approval Final
Feb 27, 2024 Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by …See details»
Positive Results for Cefepime-Enmetazobactam in Phase 3 Trial
Feb 28, 2020 More than 100 million people around the world are impacted by complicated urinary tract infections each year, leading to sizable social costs and health burden on …See details»
News - allecra
Oct 23, 2020 Allecra Therapeutics announces participation at the H.C. Wainwright annual global life sciences conference in Monte Carlo, Monaco on April 8-10,2018 Download PDF. …See details»